Analyses revealed that OPN levels were significantly higher in patient-matched recurrent metastatic tumors, both in signal intensity and percentage of OPN positivity, compared to primary breast tumors (Fig. 8b–e). This evidence concerns the gene SPP1 and metastatic neoplasm.